| |
Good morning, 360! Here's to another crazy week in the Markets🥂 Be the best prepared trader on the Street! | | FOCUS LIST🔎 | NRBO - Up over 70% in the pre-market after receiving First Site IRB approval for Phase 1 trial for the treatment of obesity | AI - Up over 16% in pre after beating earnings | OKTA - Up over 25% in pre after earnings beat | | |
Lately small biotechs are hot again 🔥 and we especially love Oncolytics Biotech (ONCY) – a clinical-stage biotechnology company at the leading edge of "immunotherapy" cancer research. | Currently, ONCY is: | 👉 Headed into Phase 3 trials. | 👉 Is sitting on massive cash. | 👉 Has FDA Fast-Track Designation | 👉 Been pegged at over 400% higher from today's price by Wall Street analysts. | | Bottom Line: ONCY could be a blockbuster opportunity from this level. With analysts raving about it, the company's sizable cash position, FDA Fast -Track designation, and a $5M award, I think the future is bright 😎 for this little company. | Only you can decide what investments fit your personal risk profile. Always trade with a solid game plan and do as much research as you can. | *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. |
|
| | HOTLIST🔥 | NRBO - Up over 70% in the pre-market after receiving First Site IRB approval for Phase 1 trial for the treatment of obesity | NeuroBo Pharmaceuticals, Inc (NRBO) is a clinical-stage biotechnology company that focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. | In the pre-market this morning, the company announced that it had received First Site IRB approval for its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity. | Fat loss drug stocks have been in play recently, for example VKTX and others, as Ozempic has been a wonder drug over recent months. | NRBO exploded up over 70% in the pre-market after the press release. | | $7.50 found some buyers in the pre-market and is a potential support level. | Above it, targets to the upside are $8, $9 and then the pre-market high at $9.72. Beyond that, $10, $12 and $14 come into play. | Below $7.50, targets to the downside are $7, $6.50, $6 and a gap to fill at $5.12. | | AI - Up over 16% in pre after beating earnings | C3.ai (AI) Inc. operates as an enterprise artificial intelligence (AI) software company in North America and internationally. The company provides C3 AI platform, an application development and runtime environment that enables customers to design, develop, and deploy enterprise AI applications. | Yesterday, in the after-hours, AI reported revenues of $78.4 million vs analyst estimates of $76.14 million. Non-GAAP EPS came in at -$0.13 vs -$0.28 expected. | The stock traded up over 15% in the pre-market after the earnings report and has been in play recently with other artificial intelligence related companies. | | The $34 area has acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $35 and then the pre-market high at $35.69. Beyond that, $36, $40 and $44 come into play. | Below $34, targets to the downside are $33.50, $33, $32.50, $32 and a gap to fill at $29.69. | | SPOTLIGHT 💡 | SMALL ACCOUNT JOURNEY | Fresh $2,000 Balance Starts March 1st |  | Reread THAT — 4.9/5 ⭐⭐⭐⭐⭐ over 1000+ Reviews! |
| Get in SAJ from the Beginning | Use Code: SAVE50 (HIT APPLY) |
|
| | OKTA - Up over 25% in pre after earnings beat | Okta, Inc. (OKTA) provides identity solutions for enterprises, small and medium-sized businesses, universities, non-profits, and government agencies in the United States and internationally. The company offers Okta's, a suite of products and services used to manage and secure identities. | In the after-hours yesterday, the company reported EPS for the quarter of $0.63 vs $0.51 expected and vs $0.30 a year ago. Revenues for the quarter ended January 2024 came in at $605 million vs $510 million year over year. | Investors cheered the earnings report and the stock traded up over 25% in the pre-market. | | The $107.50 area has acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $110 and then the pre-market high at $113.23. Beyond that, $120 and $130 come into play. | Below $107.50, there is potential support at $105, $101 and then $100 and $90 come into play. | | MARKET NEWS 📰 | | | 💥More Resources | Need improvement? Learn from Jason's favorite trading ideas under $10 | Get instant access to Jeff Bishop's top trading ideas | 💡Get the hottest stock ideas in Bright Ideas | 👊 Make sure you are getting our mobile text alerts – text "RAGE" to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the "1" at the front!). Don't miss out! | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | DISCLAIMER | *PAID ADVERTISEMENT. RagingBull has currently been paid twenty thousand dollars by ach bank transfer by Axe Communications for advertising Oncolytics Biotech Inc for a one-day advertising program. As a result of this advertisement and other marketing efforts, RagingBull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull do not hold a position in Oncolytics Biotech Inc. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Oncolytics Biotech Inc, increased trading volume, and possibly an increased share price of the Oncolytics Biotech Inc securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in Oncolytics Biotech Inc., though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company's financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. | SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. | Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull's business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. | NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. | USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as "believes," "anticipates," "estimates," "expects," "projects," "intends," or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch | TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. |
|
| | | |
|
Post a Comment
Post a Comment